Результати пошуку - Frederick L. Locke

Уточнити результати
  1. 1
    CAR T cell therapy for B-cell lymphomas

    CAR T cell therapy for B-cell lymphomas за авторством Julio C. Chávez, Frederick L. Locke

    Опубліковано 2018
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    How I Treat Cytopenias after CAR T-cell Therapy

    How I Treat Cytopenias after CAR T-cell Therapy за авторством Tania Jain, Timothy S. Olson, Frederick L. Locke

    Опубліковано 2023
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities

    Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities за авторством Bhagirathbhai Dholaria, Christina A. Bachmeier, Frederick L. Locke

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    CAR T-Cell Therapy in Large B-Cell Lymphoma

    CAR T-Cell Therapy in Large B-Cell Lymphoma за авторством Sattva S. Neelapu, Frederick L. Locke, William Y. Go

    Опубліковано 2018
    Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  5. 5
    Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma за авторством Frederick L. Locke, William Y. Go, Sattva S. Neelapu

    Опубліковано 2019
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  6. 6
    The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy

    The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy за авторством Gregory J. Kimmel, Frederick L. Locke, Philipp M. Altrock

    Опубліковано 2021
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

    Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo за авторством Yan Zheng, Yuanyuan Zha, Grégory Driessens, Frederick L. Locke, Thomas F. Gajewski

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma

    Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma за авторством Olalekan O. Oluwole, Jeroen P. Jansen, Vincent Lin, Keith Syson Chan, Sam Keeping, Lynn Navale, Frederick L. Locke

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET</scp>, <scp>ZUMA</scp>‐1, and <scp>TRANSCEND</scp> trials

    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET<... за авторством Jason R. Westin, Marie José Kersten, Gilles Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick L. Locke, Charalambos Andreadis

    Опубліковано 2021
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  10. 10
    CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

    CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations за авторством Fabiana Perna, Samir Parekh, Caroline Diorio, Melody Smith, Marion Subklewe, Rakesh Mehta, Frederick L. Locke, Nirali N. Shah

    Опубліковано 2024
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  11. 11
    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial за авторством Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch, Vadim Romanov, Frederick L. Locke, David G. Maloney

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial за авторством Richard T. Maziarz, Stephen J. Schuster, Vadim Romanov, Elisha S. Rusch, Junlong Li, James Signorovitch, David G. Maloney, Frederick L. Locke

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells

    Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells за авторством Frederick L. Locke, Zahra Mahmoudjafari, Partow Kebriaei, Rebecca Gardner, Matthew J. Frigault, Noelle V. Frey, Krishna V. Komanduri, Miguel‐Angel Perales, Sarah Nikiforow

    Опубліковано 2025
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  14. 14
    Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)

    Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel) за авторством Yuan Tian, Justin A. Budka, Frederick L. Locke, Jason R. Westin, Christina To, Gayatri Tiwari, Daqin Mao, Davide Bedognetti, Rhine R. Shen, Jorge Andrade, Simone Filosto

    Опубліковано 2025
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

    Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma за авторством Erin Dean, Gregory J. Kimmel, Matthew J. Frank, Ali Bukhari, Nasheed Hossain, Michael D. Jain, Saurabh Dahiya, David B. Miklos, Philipp M. Altrock, Frederick L. Locke

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy

    Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy за авторством Hamza Hashmi, Christina A. Bachmeier, Julio C. Chávez, Jinming Song, Mohammad Hussaini, Gabriel Krivenko, Taiga Nishihori, Hiroshi Kotani, Marco L. Davila, Frederick L. Locke, Michael D. Jain

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  17. 17
    Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

    Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' за авторством Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall

    Опубліковано 2018
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  18. 18
    End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

    End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma за авторством Caron A. Jacobson, Frederick L. Locke, David B. Miklos, Alex F. Herrera, Jason R. Westin, Jennifer Lee, John M. Rossi, Lianqing Zheng, Mauro P. Avanzi, Zachary Roberts, Jennifer K. Sun

    Опубліковано 2018
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

    4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells за авторством Emiliano Roselli, Justin C. Boucher, Gongbo Li, Hiroshi Kotani, Kristen Spitler, Kayla Reid, Estelle V. Cervantes, Yannick Bulliard, Nhan Tu, Sae Bom Lee, Bin Yu, Frederick L. Locke, Marco L. Davila

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma за авторством Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Muñoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: